Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
| 适应症 | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage III |
|---|---|
| 分期 | 2期 |
| 申办方 | University of California, San Diego |
| 状态 | 已完成 |
| 受试者人数 | 7 人 |
| 干预（药物） | Pembrolizumab, Tadalafil |
| 开始日期 | 2020年4月7日 |
| 完成日期 | 2022年4月16日 |
| 结果公布日 | 2026年2月12日 |
摘要
This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.
Rate of Dose Limiting Toxicity (DLT)
| Tadalafil and Pembrolizumab | 1 Participants |
|---|
Overall Survival (OS)
| Tadalafil and Pembrolizumab | 3 Participants |
|---|
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- Safety and Efficacy of tPBM for Epileptiform Activity in Autism — Richard Frye
- Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Th — SK Life Science, Inc.
- Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines — Rutgers, The State University of New Jersey
- Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagno — University of Virginia
- A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or — Takeda
- Maintenance TMS in Treatment Resistant Depression — Austin Messner